CSL Behring Buys Vitaeris, Picks Up Transplant Rejection Therapeutic

CSL Behring Buys Vitaeris, Picks Up Transplant Rejection Therapeutic

Source: 
BioSpace
snippet: 

CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris. The two companies inked a strategic partnership in 2017 to accelerate the development of Vitaeris’s clazakizumab. At that time, CLS Behring also had an option to acquire Vitaeris, the therapeutic, and the rest of Vitaeris’s assets.